Ronald A Li, CEO and Co-Founder at Medera, explores how human-centred preclinical models are transforming cardiovascular drug development. When we published our previous article in Drug Discovery World last September, we argued that human-based mini-Heart technology could fundamentally reshape cardiovascular drug development by reducing reliance on animal models and improving translational predictability. That argument, grounded in strong science, ultimately required patient validation. Today, that validation is emerging at scale. Over the past year, three […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!